{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:49:09Z","timestamp":1764510549787,"version":"3.46.0"},"reference-count":73,"publisher":"Practical Medicine Publishing House","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>Target therapy of chronic myeloid leukemia (CML) by tyrosine kinase inhibitors (TKI) allows to achieve high rates of the overall survival in CML. The choice of TKI treatment in every particular case should be based on individual CML patient\u2019s characteristics, including comorbidities and the risk of adverse events (AE). Every TKI has a particular toxicity profile depending on off-target action spectrum. A probability of arterial AEs on TKI therapy is comparatively low but they may be life threatening. It is highly important to evaluate this kind of AEs during a long period of vascular TKI exposure. The age-specific increased incidence of cardiovascular and respiratory diseases is an additional factor in these patients with high overall survival on TKI therapy. The article is devoted to the analysis of frequency, mechanisms, particular features, methods of diagnostics and treatment of arterial AEs emerging on second generation TKI (nilotinib and dasatinib) therapy. The detailed characteristics of arterial occlusive events on nilotinib therapy and pulmonary arterial hypertension on dasatinib are presented. Special attention is paid to the analysis of risk factors of vascular AEs and the ways to correct modified risk factors. Timely assessment of clinical symptoms of cardiopulmonary, ischemic diseases\/complications, and metabolic disorders helps to find specialized medical care (by a cardiologist, pulmonologist, endocrinologist), to prescribe an adequate therapy, provide prevention of complications and make decision about TKI dose adjustment\/switching to alternative TKI being a true foundation of safe personalized treatment in CML patients.<\/jats:p>","DOI":"10.21320\/2500-2139-2016-9-4-474-484","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T13:54:05Z","timestamp":1482155645000},"page":"474-484","source":"Crossref","is-referenced-by-count":2,"title":["Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors","\u0410\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u044b\u0435 \u0441\u043e\u0431\u044b\u0442\u0438\u044f \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u043c\u0438\u0435\u043b\u043e\u043b\u0435\u0439\u043a\u043e\u0437\u043e\u043c, \u043f\u043e\u043b\u0443\u0447\u0430\u044e\u0449\u0438\u0445 \u0442\u0435\u0440\u0430\u043f\u0438\u044e \u0438\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u0430\u043c\u0438 \u0442\u0438\u0440\u043e\u0437\u0438\u043d\u043a\u0438\u043d\u0430\u0437 2-\u0433\u043e \u043f\u043e\u043a\u043e\u043b\u0435\u043d\u0438\u044f"],"prefix":"10.21320","volume":"9","author":[{"given":"Galina Anatol\u2019evna","family":"Gusarova","sequence":"first","affiliation":[{"name":"Hematology Research Center, 4\u0430 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4a, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Turkina","sequence":"additional","affiliation":[{"name":"Hematology Research Center, 4\u0430 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4a, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8834","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"18448","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"18449","unstructured":"Martinelli G, Soverini S, Rosti G, et al. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica. 2005;90:534\u201341."},{"key":"18450","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.01.023"},{"key":"18451","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"18452","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2009.11.008"},{"key":"18453","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"18454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"18455","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"18456","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"18457","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22051"},{"key":"18458","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.04.005"},{"key":"18459","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"18460","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"18461","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.69"},{"key":"18462","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr292"},{"key":"18463","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.914.914"},{"key":"18464","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.92.92"},{"key":"18465","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.257.257"},{"key":"18466","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4018.4018"},{"key":"18467","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.7073"},{"key":"18468","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.152.152"},{"key":"18469","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4012.4012"},{"key":"18470","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000124105.39900.db"},{"key":"18471","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104075"},{"key":"18472","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.207357"},{"key":"18473","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.213637"},{"key":"18474","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.01.024"},{"key":"18475","unstructured":"\u041a\u0440\u044e\u043a\u043e\u0432 \u041d.\u041d., \u041d\u0438\u043a\u043e\u043b\u0430\u0435\u0432\u0441\u043a\u0438\u0439 \u0415.\u041d., \u041f\u043e\u043b\u044f\u043a\u043e\u0432 \u0412.\u041f. \u0418\u0448\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0431\u043e\u043b\u0435\u0437\u043d\u044c \u0441\u0435\u0440\u0434\u0446\u0430 (\u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u0430\u0441\u043f\u0435\u043a\u0442\u044b \u043a\u043b\u0438\u043d\u0438\u043a\u0438, \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0438, \u043b\u0435\u0447\u0435\u043d\u0438\u044f). \u0421\u0430\u043c\u0430\u0440\u0430, 2010. 651 \u0441."},{"key":"18476","unstructured":"[Kryukov NN, Nikolaevskii EN, Polyakov VP. Ishemicheskaya bolezn\u2019 serdtsa (Sovremennye aspekty kliniki, diagnostiki, lecheniya) (Coronary artery disease (Current aspects of clinical presentation, diagnosis, and treatment).) Samara; 2010. 651 p. (In Russ)]"},{"key":"18477","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S50779"},{"key":"18478","unstructured":"\u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0435 \u043e\u0431\u0449\u0435\u0441\u0442\u0432\u043e \u043f\u043e \u0438\u0437\u0443\u0447\u0435\u043d\u0438\u044e \u0430\u0442\u0435\u0440\u043e\u0441\u043a\u043b\u0435\u0440\u043e\u0437\u0430 (\u041d\u041e\u0410), \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0435 \u043a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u043e\u0431\u0449\u0435\u0441\u0442\u0432\u043e (\u0420\u041a\u041e), \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0435 \u043e\u0431\u0449\u0435\u0441\u0442\u0432\u043e \u043a\u0430\u0440\u0434\u0438\u043e\u0441\u043e\u043c\u0430\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0440\u0435\u0430\u0431\u0438\u043b\u0438\u0442\u0430\u0446\u0438\u0438 \u0438 \u0432\u0442\u043e\u0440\u0438\u0447\u043d\u043e\u0439 \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 (\u0420\u043e\u0441\u041e\u041a\u0420). \u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u043a\u043e\u0440\u0440\u0435\u043a\u0446\u0438\u044f \u043d\u0430\u0440\u0443\u0448\u0435\u043d\u0438\u0439 \u043b\u0438\u043f\u0438\u0434\u043d\u043e\u0433\u043e \u043e\u0431\u043c\u0435\u043d\u0430 \u0441 \u0446\u0435\u043b\u044c\u044e \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0430\u0442\u0435\u0440\u043e\u0441\u043a\u043b\u0435\u0440\u043e\u0437\u0430. \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438, V \u043f\u0435\u0440\u0435\u0441\u043c\u043e\u0442\u0440. \u041c., 2012."},{"key":"18479","unstructured":"[National Society of Atherosclerosis (NSA), Russian Cardiological Society (RCS), Russian Society of Cardiosomatic Rehabilitation and Secondary Prophylaxis (RSCR). Diagnosis and treatment of lipid metabolism impairment for prevention and treatment of atherosclerosis. National Guidelines, V edition. Moscow; 2012. (In Russ)]"},{"key":"18480","unstructured":"\u041c\u0430\u043c\u0435\u0434\u043e\u0432\u0430 \u041d.\u041c., \u0427\u0435\u043f\u0443\u0440\u0438\u043d\u0430 \u041d.\u0410. \u0421\u0443\u043c\u043c\u0430\u0440\u043d\u044b\u0439 \u0441\u0435\u0440\u0434\u0435\u0447\u043d\u043e-\u0441\u043e\u0441\u0443\u0434\u0438\u0441\u0442\u044b\u0439 \u0440\u0438\u0441\u043a: \u043e\u0442 \u0442\u0435\u043e\u0440\u0438\u0438 \u043a \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0435. \u041f\u043e\u0441\u043e\u0431\u0438\u0435 \u0434\u043b\u044f \u0432\u0440\u0430\u0447\u0435\u0439. \u041c., 2007."},{"key":"18481","unstructured":"[Mamedova NM, Chepurina NA. Summarnyi serdechno-sosudistyi risk: ot teorii k praktike. Posobie dlya vrachei. (Overall cardiovascular risk: from theory to practice.) Moscow; 2007. (In Russ)]"},{"key":"18482","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-594432"},{"key":"18483","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.052076"},{"key":"18484","unstructured":"\u0412\u0441\u0435\u0440\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0435 \u043d\u0430\u0443\u0447\u043d\u043e\u0435 \u043e\u0431\u0449\u0435\u0441\u0442\u0432\u043e \u043a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u043e\u0432. \u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u043a\u043e\u0440\u0440\u0435\u043a\u0446\u0438\u044f \u043d\u0430\u0440\u0443\u0448\u0435\u043d\u0438\u0439 \u043b\u0438\u043f\u0438\u0434\u043d\u043e\u0433\u043e \u043e\u0431\u043c\u0435\u043d\u0430 \u0441 \u0446\u0435\u043b\u044c\u044e \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0430\u0442\u0435\u0440\u043e\u0441\u043a\u043b\u0435\u0440\u043e\u0437\u0430. \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438, IV \u043f\u0435\u0440\u0435\u0441\u043c\u043e\u0442\u0440. \u041c., 2009."},{"key":"18485","unstructured":"[Russian Scientific Cardiologists\u2019 Society. Diagnosis and treatment of lipid metabolism impairment for prevention and treatment of atherosclerosis. National Guidelines, IV edition. Moscow; 2009. (In Russ)]"},{"key":"18486","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530120067043"},{"key":"18487","unstructured":"Tasigna [prescribing Information]. East Hanover, NJ: Novartis Pharmaceutical Corp.; 2015. [Internet] Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022068s0211bl.pdf (accessed 15.06.2016)."},{"key":"18488","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"18489","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.6512"},{"key":"18490","unstructured":"\u0413\u0443\u0441\u0430\u0440\u043e\u0432\u0430 \u0413.\u0410., \u0422\u0443\u0440\u043a\u0438\u043d\u0430 \u0410.\u0413., \u0412\u043e\u0440\u043e\u043d\u0446\u043e\u0432\u0430 \u0410.\u0412. \u0438 \u0434\u0440. \u041e\u0442\u0434\u0430\u043b\u0435\u043d\u043d\u044b\u0435 \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0434\u0430\u0437\u0430\u0442\u0438\u043d\u0438\u0431\u043e\u043c \u0438 \u0430\u043d\u0430\u043b\u0438\u0437 \u043e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0435\u0439 \u0442\u0435\u0447\u0435\u043d\u0438\u044f \u043f\u043b\u0435\u0432\u0440\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u0432\u044b\u043f\u043e\u0442\u0430 \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0432 \u043f\u043e\u0437\u0434\u043d\u0435\u0439 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0444\u0430\u0437\u0435 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043c\u0438\u0435\u043b\u043e\u043b\u0435\u0439\u043a\u043e\u0437\u0430 \u043f\u043e\u0441\u043b\u0435 \u043d\u0435\u0443\u0434\u0430\u0447\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0438\u043c\u0430\u0442\u0438\u043d\u0438\u0431\u043e\u043c. \u0411\u044e\u043b\u043b\u0435\u0442\u0435\u043d\u044c \u0421\u041e \u0420\u0410\u041c\u041d. 2014;34(6):27\u201335."},{"key":"18491","unstructured":"[Gusarova GA, Turkina AG, Vorontsova AV, et al. Long-term results of therapy by dasatinib and features analysis of the pleural effusion course in patients at late chronic phase of chronic myeloid leukemia after imatinib treatment failure. Byulleten\u2019 SO RAMN. 2014;34(6):27\u201335. (In Russ)]"},{"key":"18492","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"18493","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415"},{"key":"18494","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"18495","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00154210"},{"key":"18496","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-11-30"},{"key":"18497","unstructured":"Philibert L, Cazorla C, Peyriere H, et al. Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. Fund Clin Pharmacol. 2011;25:95."},{"key":"18498","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.08.007"},{"key":"18499","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.7472"},{"key":"18500","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035913"},{"key":"18501","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-013-3765-7"},{"key":"18502","unstructured":"Patkowska E, Lech-Maranda E, Darocha S, et al. Reversible pulmonary arterial hypertension as a complication of dasatinib treatment, with efficacious and safe continuation of chronic myeloid leukaemia therapy with nilotinib. Hematologica. 2013;4(1):76\u201383."},{"key":"18503","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02692"},{"key":"18504","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1995250"},{"key":"18505","doi-asserted-by":"publisher","DOI":"10.5543\/tkda.2015.41763"},{"key":"18506","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2014.11.010"},{"key":"18507","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"18508","unstructured":"Saglio G, Le Coutre P, Cortes J, et al. Safety and tolerability of dasatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL), pooled analysis of over 2400 patients. Poster presented at: The 19th Congress of the European Hematology Association (EHA) Annual Meeting; June 12\u201315, 2014; Milan, Italy."},{"key":"18509","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.012"},{"key":"18510","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24174"},{"key":"18511","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System. US Food and Drug Administration, Silver Spring, MD. [Internet] Available from: http:\/\/www.fda.gov\/cder\/aers\/default.htm (accessed 10.04.2015)."},{"key":"18512","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"18513","unstructured":"Novartis Efficacy, safety, tolerability and pharmacokinetics (pk) of nilotinib (AMN 107) in pulmonary arterial hypertension (PAH). [Internet] Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179737 (accessed 20.04.2015)."},{"key":"18514","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2795"},{"key":"18515","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"18516","unstructured":"Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2015. [Internet] Available from: http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf (accessed 15.06.2016)."},{"key":"18517","unstructured":"\u0421\u0430\u0434\u044b\u043a\u043e\u0432\u0430 \u0414.\u0418. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u043f\u043e\u0434\u0445\u043e\u0434\u044b \u043a \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u043b\u0435\u0433\u043e\u0447\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u0435\u043d\u0437\u0438\u0438. \u041f\u0440\u0430\u043a\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0430. 2012;7(62):21\u20136."},{"key":"18518","unstructured":"[Sadykova DI. Modern approaches to diagnostic and treatment of pulmonary hypertension. Prakticheskaya meditsina. 2012;7(62):21\u20136. (In Russ)]"},{"key":"18519","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1356494"},{"key":"18520","unstructured":"Galie N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur Heart J. 2009;30(20):2493\u2013537. doi: 1093\/eurheartj\/ehp297."}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/517\/479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/517\/479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:24:23Z","timestamp":1764501863000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2016-9-4-474-484","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"type":"electronic","value":"2500-2139"},{"type":"print","value":"1997-6933"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}